Loading
Trials recruiting now, the landmark trials, the key papers and what they mean, the latest literature, and the milestones year by year.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
MOMENTUM addressed the biggest gap left by ruxolitinib: patients whose anaemia makes standard JAK inhibition hard to give. Momelotinib is now the preferred option for anaemic, previously treated myelofibrosis and is being adopted in first line for anaemic patients. The absolute symptom benefit is modest and durable disease modification has not been shown.
COMFORT-I turned the 2005 discovery of the JAK2 V617F mutation into the first effective medicine for myelofibrosis, transforming symptom control for a disease with no prior standard. Ruxolitinib is still the reference first-line therapy, with fedratinib, pacritinib and momelotinib as alternatives for cytopenic patients. It does not eliminate the malignant clone or reverse fibrosis in most patients.
With COMFORT-I, the evidence for ruxolitinib as the first approved treatment for myelofibrosis and for JAK inhibition as the standard for spleen and symptom control.
Query for this cancer: (TITLE:"Myeloproliferative neoplasms" OR ABSTRACT:"Myeloproliferative neoplasms" OR TITLE:"PV, ET, myelofibrosis" OR ABSTRACT:"PV, ET, myelofibrosis" OR TITLE:"MPN" OR ABSTRACT:"MPN" OR TITLE:"Polycythaemia vera" OR ABSTRACT:"Polycythaemia vera" OR TITLE:"Essential thrombocythaemia" OR ABSTRACT:"Essential thrombocythaemia" OR TITLE:"Primary myelofibrosis" OR ABSTRACT:"Primary myelofibrosis") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Myeloproliferative neoplasms (PV, ET, myelofibrosis), not a curated reading list.
Proposes that PV, ET, CML and myelofibrosis are related myeloproliferative disorders.
Four groups report the mutation in most PV and half of ET/PMF; the first molecular marker for BCR-ABL1-negative MPN.
COMFORT-I/II: spleen and symptom benefit in myelofibrosis; the first JAK inhibitor.
Klampfl and Nangalia find CALR exon 9 mutations in most JAK2-negative ET/PMF.
CYTO-PV: keeping haematocrit <45% cuts cardiovascular death and major thrombosis in PV.
JAKARTA; the second JAK inhibitor after an eight-year gap.
PROUD/CONTINUATION-PV: superior long-term haematologic and molecular response versus hydroxyurea.
MOMENTUM: symptom, spleen and transfusion-independence benefit versus danazol.
VERIFY: hepcidin mimetic controls erythrocytosis without phlebotomy; FDA approval August 2026.